

School of Basic and Applied Sciences

BioScience
ETE - Jun 2023

Time : 3 Hours

Marks : 50

Sem II - MBACRT2001 - Regulatory Affairs And Ethics In Clinical Research

Your answer should be specific to the question asked

Draw neat labeled diagrams wherever necessary

- | | | |
|-----|---|------------|
| 1. | Describe Inspection in clinical studies. | K2 CO4 (2) |
| 2. | Describe monitoring in clinical research. | K1 CO3 (2) |
| 3. | Describe Quality assurance in clinical trials. | K2 CO5 (2) |
| 4. | Describe serious adverse event. | K2 CO2 (2) |
| 5. | Define adverse drug reaction. | K1 CO1 (2) |
| 6. | Express the 21 CFR part 11 and part 50 | K4 CO6 (6) |
| 7. | Demonstrate ethics committee composition and their roles in detail. | K3 CO1 (5) |
| 8. | Elucidate tuskgee experiment and Nuremberg code importance. | K4 CO2 (5) |
| 9. | Evaluate the Sponsor role to maintain the integrity and quality of clinical research. | K4 CO5 (8) |
| 10. | Evaluate the points that need to be mentioned under informed consent process and the necessity of it in clinical research. | K3 CO3 (8) |
| 11. | Analyze the declaration of Helsinki and Belmont report and changes happened in clinical research industry after these two guidelines. | K4 CO4 (8) |